MedPath

Commons, Marty

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Phase 3
Active, not recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: canakinumab-matching placebo
First Posted Date
2018-08-15
Last Posted Date
2024-10-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
673
Registration Number
NCT03631199
Locations
πŸ‡ΊπŸ‡Έ

Pacific Shores Medical Group ., Long Beach, California, United States

πŸ‡ΊπŸ‡Έ

USC Kenneth Norris Comprehensive Cancer Center ., Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Advent Health Cancer Institute, Orlando, Florida, United States

and more 2 locations

Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Phase 3
Withdrawn
Conditions
Acute Lymphoblastic Leukemia
Interventions
Biological: Tisagenlecleucel
First Posted Date
2018-08-14
Last Posted Date
2020-07-09
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT03628053

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Phase 3
Terminated
Conditions
Asthma
Interventions
Drug: QAW039 150 mg once daily
Drug: QAW039 450 mg once daily
Drug: Placebo once daily
First Posted Date
2018-08-14
Last Posted Date
2021-10-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
604
Registration Number
NCT03629249
Locations
πŸ‡»πŸ‡³

Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1
Completed
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Biological: Tisagenlecleucel
First Posted Date
2018-08-14
Last Posted Date
2022-08-15
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
12
Registration Number
NCT03630159
Locations
πŸ‡ΊπŸ‡Έ

Emory University School of Medicine SC CTL019, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

University of Kansas Hospital and Medical Center U of Kansas Cancer Center, Kansas City, Kansas, United States

πŸ‡ΊπŸ‡Έ

University of Chicago Medical Center Hematology and Oncology, Chicago, Illinois, United States

and more 1 locations

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Phase 3
Terminated
Conditions
Non-Small-Cell Lung
Interventions
Other: Placebo
First Posted Date
2018-08-13
Last Posted Date
2023-08-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
245
Registration Number
NCT03626545
Locations
πŸ‡ΊπŸ‡Έ

University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States

πŸ‡ΊπŸ‡Έ

Montefiore Medical Center Albert Einstein College of Med, Bronx, New York, United States

πŸ‡ΊπŸ‡Έ

Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Phase 3
Completed
Conditions
Multiple Sclerosis
Relapsing Multiple Sclerosis
Advancing Multiple Sclerosis
Interventions
First Posted Date
2018-08-09
Last Posted Date
2024-06-20
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
185
Registration Number
NCT03623243
Locations
πŸ‡΅πŸ‡·

Novartis Investigative Site, Guaynabo, Puerto Rico

πŸ‡ΊπŸ‡Έ

MS & Neuromuscular Center of Excellence, Clearwater, Florida, United States

πŸ‡ΊπŸ‡Έ

Alabama Neurology Associates, Homewood, Alabama, United States

and more 1 locations

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.

Phase 2
Completed
Conditions
Lupus Nephritis
Interventions
Drug: Placebo
First Posted Date
2018-08-01
Last Posted Date
2024-10-09
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
57
Registration Number
NCT03610516
Locations
πŸ‡ΉπŸ‡·

Novartis Investigative Site, Kocaeli, Turkey

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Phase 2
Completed
Conditions
Non-Hodgkin Lymphoma
Interventions
Biological: Tisagenlecleucel
Drug: lymphodepleting chemotherapy
Drug: Bridging Therapy
First Posted Date
2018-08-01
Last Posted Date
2024-06-20
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
34
Registration Number
NCT03610724
Locations
πŸ‡ΊπŸ‡Έ

Childrens Hospital Los Angeles, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Johns Hopkins Oncology Center ORA, Baltimore, Maryland, United States

πŸ‡ΊπŸ‡Έ

Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States

and more 8 locations

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Phase 1
Completed
Conditions
Renal Impairment
Interventions
First Posted Date
2018-07-30
Last Posted Date
2021-10-12
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
14
Registration Number
NCT03605277
Locations
πŸ‡©πŸ‡ͺ

Novartis Investigative Site, Berlin, Germany

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
First Posted Date
2018-07-26
Last Posted Date
2024-10-28
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT03601442
Locations
πŸ‡ΊπŸ‡Έ

Banner MDACC, Gilbert, Arizona, United States

πŸ‡ΊπŸ‡Έ

University of Arizona Cancer Center, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Phoenix Children's Hospital, Phoenix, Arizona, United States

and more 140 locations
Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy